EYEGENE Inc.

Renhaim Therapeutics EG-COVID VITAL DB BIOVIA

ABOUT US
R&D
- R&D Center Introduction
  - Pipeline
  - R&D Performance
- Core Technology
  - Ischemic Disease
  - Premium Vaccine
BUSINESS AREAS
- New Business
- Network
NOTICES
- Stock Information

ABOUT US
R&D
R&D Center Introduction
Core Technology
- Ischemic Disease
- Premium Vaccine
BUSINESS AREAS
New Business
NETWORK
- Network
NOTICES
- Stock Information

전체메뉴닫기

Popup Layer Notification

No pop-up layer notifications.

Open the secrets of the human body

State of the art
technology to light the
world with vaccines and
innovative drugs

For the affluent future of mankind

Korean Biopharmaceutical
that never ceases
to stop research

Slow down and Enjoy your life

For New Old Age

ABOUT EYEGENE

Clinical stage biopharmaceutical developing vaccines and new innovative recombinant protein drugs

EyeGene took its first step in the development of innovative biopharmaceutical drugs when it was first established in June 2000. Since then, EyeGene’s R&D Scientists have continued to research and develop innovative drugs for the treatment and prevention of age-related diseases.

Corporate Overview EyeGene's History

TECHNOLOGIES

PRODUCT PIPELINE

Ischemic Disease Technologies Vaccine Technologies

BUSINESS AREAS

NEW BUSINESS

Health Functional Food
BIO IT
Pharmaceutical Wholesale

T. +82-2-322-1687
F. +82-2-302-4359(Head Office) / +82-2-324-8059(R&D Center)
Head Office : B-1211, 401 Yangcheon-ro, Gangseo-gu, Seoul, 07528, Korea
R&D Center : 2F, 122-1, Uijang-ro, Deogyang-gu, Goyang-si, Gyeonggi-do, 10551, Korea